MNTA: There are clearly several different possibilities to include FDA rejection of Teva/Amphastar's ANDA's at the same time as an approval for MNTA. Bottom line: If MNTA gets approval for M-Enoxaparin, any subsequent event timing regarding marketing will pale in comparison to the right to market the generic in the first place. Win-win any way we spin it. Let's just get the approval and go from there, since there are currently too many variables.
News 
Market Data 
Discover 
AI
